A practical reference on peptide backbone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-04 and is reviewed periodically as new material appears.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
In many metabolic reactions, a protein that acts as an electron carrier binds to an enzyme that acts as its reductase. After it receives an electron, it dissociates and then binds to the next enzyme that acts as its oxidase (i.e. an acceptor of the electron). These interactions between proteins are dependent on highly specific binding between proteins to ensure efficient electron transfer. Examples: mitochondrial oxidative phosphorylation chain system components cytochrome c-reductase / cytochrome c / cytochrome c oxidase; microsomal and mitochondrial P450 systems. In the case of the mitochondrial P450 systems, the specific residues involved in the binding of the electron transfer protein adrenodoxin to its reductase were identified as two basic Arg residues on the surface of the reductase and two acidic Asp residues on the adrenodoxin. More recent work on the phylogeny of the reductase has shown that these residues involved in protein–protein interactions have been conserved throughout the evolution of this enzyme.
=== TEX86 === Because the number of cyclopentane moieties in a GDGT compound is related to the temperature of the growth environment, with increasing numbers of cyclopentane rings resulting in increased thermal stability and allowing for survival at higher temperatures, GDGT distribution and abundance can be employed as paleoclimate proxies. TEX86 is one such paleothermometer which relates distribution and relative abundance of GDGT-1, GDGT-2, GDGT-3, and crenarchaeol isomer to past sea surface temperature (SST) (see TEX86). GDGT-0, GDGT-4, and crenarchaeol are excluded from consideration for this proxy due to their very high abundances relative to isoGDGTs 1–3. The relationship between isoGDGT distribution and temperature is not linear, and some studies have demonstrated its distinctive bias towards unrealistically cold temperatures in the lower latitudes. Current research suggests TEX86 works best in the temperature range 15-34 degrees Celsius. Seasonal variability in archaeal productivity and depth in the water column at which the archaea grow should be considered prior to employing this proxy.
They bear much of the basic features provided by cell membranes. Proteinoid-based protocells enclosing RNA molecules could have been the first cellular life forms on Earth. Another possibility is that the shores of the ancient coastal waters may have been a suitable environment for the initial development of cells. Waves breaking on the shore create a delicate foam composed of bubbles. Shallow coastal waters also tend to be warmer, further concentrating the molecules through evaporation. While bubbles made mostly of water tend to burst quickly, oily bubbles are much more stable. The phospholipid, the primary material of cell membranes, is an example of a common oily compound prevalent in the prebiotic seas. Both of these options require the presence of massive amounts of chemicals and organic material in order to form cells. A large gathering of organic molecules most likely came from what scientists now call the prebiotic soup. The prebiotic soup refers to the collection of every organic compound that appeared on Earth after it was formed. This soup would have most likely contained the compounds necessary to form early cells. Phospholipids are composed of a hydrophilic head on one end and a hydrophobic tail on the other. They can come together to form a bilayer membrane. A lipid monolayer bubble can only contain oil and is not conducive to harboring water-soluble organic molecules. On the other hand, a lipid bilayer bubble can contain water and was a likely precursor to the modern cell membrane.
The brain-to-blood ratio, or brain–blood ratio, is a statistic in pharmacokinetics defined as the ratio of a drug's brain concentrations relative to its circulating blood concentrations. It is a measure of the ability of a drug to cross the blood–brain barrier and exert effects in the central nervous system. Determinants of brain-to-blood ratio include physicochemical properties like molecular volume, molecular weight, polar surface area, charge state, hydrogen bonding (related to quantity of nitrogen and oxygen atoms), and hydrophilicity–lipophilicity. Other factors include plasma protein binding, active transport across the blood–brain barrier either into the brain or out of the brain by membrane transport proteins (transporters), and degree of binding to components of brain tissue. An example of brain-to-blood ratio can be made with beta blockers. The highly lipophilic beta blocker propranolol has a brain-to-blood ratio in humans of 15:1 to 26:1, whereas the hydrophilic beta blocker atenolol is peripherally selective with a blood-to-brain ratio of 0.2:1.
==== United States ==== Luvesilocin is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
Sources: en.wikipedia.org
=== Draft and minor leagues === The Boston Red Sox selected Bagwell in the fourth round (110th overall) of the 1989 Major League Baseball draft. Throughout his career, Barry Axelrod served as his agent. For his first professional assignment, the Red Sox appointed Bagwell to the Single-A Winter Haven Red Sox of the Florida State League in 1989, where he batted .310 with two home runs. In 1990, while playing for the Double-A New Britain Red Sox, Bagwell won the Eastern League Most Valuable Player Award. In 136 games with New Britain, he batted .333 with 160 hits, four home runs (HR), 61 runs batted in (RBI), 34 doubles, seven triples, 73 bases on balls (BB or walks), 57 strikeouts (SO), .422 on-base percentage (OBP), .457 slugging percentage (SLG) and .880 on-base plus slugging percentage (OPS). He finished first in the league in hits and doubles, second in batting, OBP and OPS, fourth in walks, fifth in SLG, ninth in runs scored and tenth in RBI. Late in the 1990 season, the Red Sox, who were in search of relief pitching to improve their chances of making the playoffs, contacted the Houston Astros about Larry Andersen. Stan Benjamin, who scouted the New England region for the Astros, recommended that they ask for Bagwell in return. The Astros initially hesitated owing to his sparse home run production, but Benjamin persuaded them, quipping that New Britain's Beehive Field was so large that "Babe Ruth couldn't hit home runs in that ballpark."[a] On August 30, 1990, the Red Sox took the Astros' offer.
The importation of mephedrone into the UK was banned on 29 March 2010. The next day, the ACMD in the UK published a report on the cathinones, including mephedrone, and recommended they be classified as Class B drugs. On 7 April 2010, the Misuse of Drugs Act 1971 (Amendment) Order 2010 was passed by parliament, making mephedrone and other substituted cathinones, Class B drugs from 16 April 2010. Prior to the ban taking effect, mephedrone was not covered by the Misuse of Drugs Act 1971. It was, though, an offence under the Medicines Act to sell it for human consumption, so it was often sold as "plant food" or "bath salts", although it has no use as these products; this, too, was possibly illegal under the Trade Descriptions Act 1968. In the US, similar descriptions have been used to describe mephedrone, as well as methylenedioxypyrovalerone (MDPV). In May 2010, the Republic of Ireland made mephedrone illegal, followed by Belgium, Italy, Lithuania, France and Norway in June and Russia in July. In August 2010, Austria and Poland made it illegal and China announced it would be illegal as of 1 September 2010. Mephedrone had been reported to be used in Singapore in February 2010, but it was made illegal in November 2010. In December 2010, following the advice of the EMCDDA, mephedrone was made illegal throughout the EU, a move Switzerland also made shortly afterwards. Countries which have not already banned it, such as the Netherlands, Greece and Portugal, will need to change legislation to comply with the EU ruling.
Isotope masses from: Audi, Georges; Bersillon, Olivier; Blachot, Jean; Wapstra, Aaldert Hendrik (2003), "The NUBASE evaluation of nuclear and decay properties", Nuclear Physics A, 729: 3–128, Bibcode:2003NuPhA.729....3A, doi:10.1016/j.nuclphysa.2003.11.001 Half-life, spin, and isomer data selected from the following sources. Audi, Georges; Bersillon, Olivier; Blachot, Jean; Wapstra, Aaldert Hendrik (2003), "The NUBASE evaluation of nuclear and decay properties", Nuclear Physics A, 729: 3–128, Bibcode:2003NuPhA.729....3A, doi:10.1016/j.nuclphysa.2003.11.001 National Nuclear Data Center. "NuDat 3.0 database". Brookhaven National Laboratory. Holden, Norman E. (2004). "11. Table of the Isotopes". In Lide, David R. (ed.). CRC Handbook of Chemistry and Physics (85th ed.). Boca Raton, Florida: CRC Press. ISBN 978-0-8493-0485-9.
== History == They were first characterized in 1907 by Siegfried Oberndorfer, a German pathologist at LMU Munich, who coined the term karzinoide, or "carcinoma-like", to describe the unique feature of behaving like a benign tumor despite having a malignant appearance microscopically. The recognition of their endocrine-related properties was later described by Gosset and Masson in 1914, and these tumors are now known to arise from the enterochromaffin (EC) and enterochromaffin-like (ECL) cells of the gut. Some sources credit Otto Lubarsch with the discovery.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.